Teva To Present Data Demonstrating UZEDY Extended-Release Injectable Suspension Significantly Prolonged Time To Impending Relapse For Adults With Schizophrenia At The American Psychiatric Association's 2023 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceuticals will present data at the American Psychiatric Association's 2023 Annual Meeting, demonstrating that UZEDY, an extended-release injectable suspension, significantly prolonged time to impending relapse for adults with schizophrenia. The FDA approved UZEDY on April 28, 2023.
May 20, 2023 | 7:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Teva Pharmaceuticals will present positive data on UZEDY, an FDA-approved injectable suspension for schizophrenia treatment, at the American Psychiatric Association's 2023 Annual Meeting.
The presentation of positive data on UZEDY at the APA's 2023 Annual Meeting will likely generate interest and attention from the medical community, potentially leading to increased adoption of the treatment. This could result in increased revenues for Teva Pharmaceuticals, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100